MEDFORD, MASSACHUSETTS – November 2, 2021 – Travera announced today the publication of the results of a study which confirms the potential clinical utility of the company’s testing approach to predicting a patient’s response to cancer drugs based on subtle changes in the mass of individual tumor cells. The paper, entitled “Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models,” published in the journal Cell Reports, is based on a study conducted by researchers from the Massachusetts Institute of Technology (MIT), the Koch Institute for Integrative Cancer Research, Dana-Farber Cancer Institute, Brigham & Women’s Hospital and Boston Children’s Hospital. The authors conclude that the use of cell mass is a promising functional biomarker for cancers and associated drug treatments with particular importance for patients who lack genomic biomarkers.
“The results from this study confirm that single-cell mass measurements can be used to for drug susceptibility testing and that Travera’s Suspended Microchannel Resonator (SMR) mass assay can be used in individual patients to predict overall survival following cancer drug treatment, “stated Clifford Reid, Ph.D., Travera’s CEO. “This data builds on the results from previous studies which provided initial evidence of the value of our approach to biomarker testing for cancer patients.”
Click here to view a copy of the publication.
Travera was founded in 2017 to commercialize a breakthrough measurement technology and biomarker developed in the Manalis Laboratory in the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT). The company’s initial test is based on this technology; a new measurement tool called the Suspended Microchannel Resonator (SMR) that makes exquisitely precise measurements of the effects of cancer drugs on cancer cells.